TL;DR
Cognito Therapeutics’ Spectris headset failed to significantly slow decline on the trial’s primary measure in a Phase 3 study of 673 people with mild-to-moderate Alzheimer’s. A prespecified analysis suggested possible benefit on some measures among participants with mild disease, but experts cautioned that the subgroup findings are not conclusive. The company said it will discuss the results with the FDA.
Cognito Therapeutics’ Spectris headset, which delivers light and sound stimulation at 40 Hz, failed to significantly slow decline compared with a sham device in a Phase 3 trial involving 673 people with mild-to-moderate Alzheimer’s disease. The result misses the study’s main goal and leaves the device’s potential clinical benefit unestablished, although researchers reported a possible signal in a subgroup with mild Alzheimer’s.
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Neurologist Dr. Marwan Sabbagh presented the pivotal HOPE trial results at the 19th annual Clinical Trials on Alzheimer’s Disease conference in Boston. Participants were randomly assigned to use either Spectris or a sham headset for 60 minutes a day over one year. The main outcome measured change on a 108-point scale combining cognition and everyday functioning. Spectris did not significantly outperform the sham treatment on that measure.
The trial assessed participants at the start and every three months, with a further safety follow-up one month after treatment ended. Although the device was described as well tolerated and no unanticipated side effects were reported, 403 participants—about 60% of those enrolled—completed the study. Headaches were reported by 5.7% of people using Spectris and 3.9% using the sham device, according to the report.
Researchers also examined a prespecified subgroup of participants with mild Alzheimer’s. In that group, results suggested possible slowing on three of five assessed measures. The analysis was planned before the trial, but researchers did not adjust for the multiple comparisons. That limitation can raise the chance of a finding occurring by chance, particularly when the overall primary result is negative. The available report does not establish that the subgroup signal reflects a reliable treatment effect.
A Setback for 40 Hz Stimulation
The result weakens the case that this particular 40 Hz audiovisual approach can slow Alzheimer’s-related decline across a broad mild-to-moderate population. The trial tested whether daily stimulation could produce a measurable difference in both cognition and daily function; it did not show a significant benefit on its primary combined measure. That matters because a large, controlled Phase 3 study is intended to provide pivotal evidence about whether an intervention works well enough to support further development or regulatory review.
The finding does not establish that all 40 Hz stimulation approaches are ineffective, nor does the subgroup analysis establish that Spectris benefits people with mild disease. For patients and families, the device should not be treated as a proven way to slow Alzheimer’s on the basis of these results. The completion rate also leaves questions about how practical sustained daily use was for participants over a year, even though the report says the device was generally tolerated.
Products Worth Considering

Garmin Forerunner 970 GPS Running and Triathlon Smartwatch, 47mm, Carbon Gray DLC Titanium with Black/Whitestone Band

Oura Ring 5 Smart Ring, Silver, Size 8

Levoit Core 400S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
From Early Research to HOPE
The approach is based on the idea that rhythmic electrical activity known as gamma waves, associated with processes including memory and attention, may be disrupted in Alzheimer’s. Spectris aims to stimulate these rhythms with synchronized light and sound at 40 Hz. Cognito Therapeutics was founded by MIT neuroscientists Ed Boyden and Li-Huei Tsai, whose mouse research helped motivate work on the approach. Early research and animal findings, however, do not by themselves show that a device improves outcomes for people with Alzheimer’s.
A prior Phase 2 study did not find a significant effect on a combined measure of cognition and function, though it showed signs that prompted further testing, including possible effects on decline and brain shrinkage. The HOPE study then tested the headset in a larger group over a year. Its negative primary result is the central finding from the pivotal trial; the mild-disease subgroup observation is secondary evidence that requires cautious interpretation.
“The data “isn’t very convincing.””
— Robert Alexander, chief scientific officer of the Alzheimer’s Prevention Initiative, as quoted by Being Patient
Subgroup Signal Needs Testing
It is not yet clear whether the apparent signal among participants with mild Alzheimer’s reflects a real effect. The subgroup was specified in advance, but the reported analysis covered several measures without adjustment for multiple comparisons, and the overall primary outcome was negative. Experts quoted in the report said a further study would be needed to determine whether the device affects cognition, daily function, or both in that population.
The report also does not give the full numerical results for each outcome, the reasons participants left the study, or a detailed account of how missing data affected the analysis. While it says there were no unanticipated side effects, the completion rate and daily-use schedule leave practical questions about adherence over longer periods. The FDA’s view of the evidence, the company’s regulatory plans, and whether it will run another trial remain unknown.
FDA Discussions and Further Testing
Cognito Therapeutics said it plans to engage with the FDA to discuss whether the HOPE results could support a medical device filing. No approval decision or filing was reported, and the company’s statement does not establish that the agency will consider the current evidence sufficient.
A confirmatory study focused on people with mild symptomatic Alzheimer’s could help establish whether the subgroup finding is reproducible. Any such trial would also need to address the high share of participants who did not complete HOPE, as Bozoki said trial retention and adherence would need improvement. The source report does not identify a study start date or provide a timeline for the company’s discussions with regulators.
Key Questions
Did Spectris meet the main goal of the Phase 3 trial?
No. The headset did not significantly outperform a sham device on the trial’s primary 108-point measure combining cognition and daily functioning.
Did the trial show any possible benefit?
A prespecified analysis of participants with mild Alzheimer’s suggested possible slowing on three of five measures. The finding is uncertain: the analysis involved multiple comparisons without adjustment, and the overall trial result was negative.
How was Spectris used in the study?
Participants were assigned to Spectris or a sham headset and were asked to use their device for 60 minutes a day for one year. Spectris delivered light and sound at a 40 Hz frequency.
Was the headset safe and well tolerated?
The report says the device was well tolerated and that no unanticipated side effects occurred. Headaches were reported by 5.7% of Spectris users and 3.9% of sham users. About 60% of enrolled participants completed the study, and the reasons for non-completion were not detailed in the supplied report.
What happens next for the device?
Cognito said it will discuss the results with the FDA to determine whether they are sufficient for a medical device filing. The company has not, in the reported material, announced a filing, an approval, or a timeline for a further confirmatory trial.
Source: beingpatient.com
